Cargando…

Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure

BACKGROUND: In our study, we have hypothesized that proviral DNA may show the history of mutations that emerged at previous failures to a Raltegravir containing regimen, in patients who are currently undetectable and candidates to simplification to a Dolutegravir containing regimen, in order to deci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández-Caballero, Jose Ángel, Chueca, Natalia, Álvarez, Marta, Mérida, María Dolores, López, Josefa, Sánchez, José Antonio, Vinuesa, David, Martínez, María Ángeles, Hernández, José, García, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866296/ https://www.ncbi.nlm.nih.gov/pubmed/27177767 http://dx.doi.org/10.1186/s12879-016-1545-8

Ejemplares similares

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Unprocessed Viral DNA Could Be the Primary Target of the HIV-1 Integrase Inhibitor Raltegravir
por: Ammar, Farah F., et al.
Publicado: (2012)

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen
por: Cavaco-Silva, Joana, et al.
Publicado: (2014)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
por: Machado, Lucas de Almeida, et al.
Publicado: (2019)

Use of deep sequencing data for routine analysis of HIV resistance in newly diagnosed patients
por: Fernández-Caballero, Jose-Angel, et al.
Publicado: (2014)

A point mutation in HIV-1 integrase redirects proviral integration into centromeric repeats
por: Winans, Shelby, et al.
Publicado: (2022)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection
por: Santos, Carla Regina Gomes Rodrigues, et al.
Publicado: (2022)

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs
por: Puertas, Maria C, et al.
Publicado: (2018)

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions
por: Reigadas, Sandrine, et al.
Publicado: (2010)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
por: Noguera-Julian, Marc, et al.
Publicado: (2013)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial
por: Hulgan, Todd, et al.
Publicado: (2014)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors
por: Meixenberger, Karolin, et al.
Publicado: (2017)

Persistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patient
por: Trabaud, MA, et al.
Publicado: (2014)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
por: Delelis, Olivier, et al.
Publicado: (2009)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
por: Orta-Resendiz, Aurelio, et al.
Publicado: (2020)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Pyrosequencing Analysis Reveals Changes in Intestinal Microbiota of Healthy Adults Who Received a Daily Dose of Immunomodulatory Probiotic Strains
por: Plaza-Díaz, Julio, et al.
Publicado: (2015)

Mutations altering acetylated residues in the CTD of HIV-1 integrase cause defects in proviral transcription at early times after integration of viral DNA
por: Winans, Shelby, et al.
Publicado: (2020)

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
por: Ni, Xiao-Ju, et al.
Publicado: (2011)

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
por: Depatureaux, Agnès, et al.
Publicado: (2014)

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment
por: El Bouzidi, Kate, et al.
Publicado: (2020)

HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure
por: van Hal, Sebastiaan J, et al.
Publicado: (2009)

Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy
por: López Zúñiga, Miguel Ángel, et al.
Publicado: (2020)

4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4j52jv9f9it8j46k5vphuobec1